Navigation Links
Labopharm appeals FDA's decision on once-daily tramadol
Date:10/15/2007

LAVAL, QC, Oct. 15 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today announced that it has initiated the U.S. Food and Drug Administration (FDA)'s Formal Dispute Resolution process, appealing the Agency's decision regarding the Company's once-daily formulation of tramadol. Labopharm received a second Approvable Letter from the FDA for its once-daily formulation of tramadol in May of this year. The Company firmly believes it has met the statutory standards for approval of its once-daily tramadol formulation.

About the FDA's Formal Dispute Resolution Process

FDA regulations provide a mechanism for those seeking regulatory approval of a drug product through a New Drug Application (NDA) to obtain formal review of any Agency decision through a Formal Dispute Resolution process by raising the matter with the supervisor of the employee who made the decision. If the issue is not resolved at the primary supervisory level, the applicant may request that the matter be reviewed at the next higher supervisory level. This process may continue through the Agency's chain of command, through the Centers to the Commissioner of Food and Drugs. The Formal Dispute Resolution process exists to encourage open, prompt discussion of scientific (including medical) disputes and procedural (including administrative) disputes that arise during the drug development, new drug review, generic drug review, and post-marketing oversight processes.

About Labopharm Inc.

Labopharm is an emerging leader in optimizing the performance of existing small molecule drugs using its proprietary controlled-release technologies. The Company's lead product, a unique once-daily formulation of tramadol, is being commercially launched in key markets globally. The Company also has a robust pipeline of follow-on products in both pre-clinical and clinical development. Labopharm's vision is to become a fully integrated, international, specialty pharmaceutical company wit
'/>"/>

SOURCE Labopharm Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Kalam Appeals to Eradicate Hearing Disability
2. UNAIDS Chief Appeals for Projects to Battle AIDS/HIV
3. Man Appeals to President to Save His Ailing Son
4. Appeals Against The New Resolution By NICE Increases
5. Unicef Appeals To Prioritize Children In Fight Against AIDs
6. Swiss Group Appeals Invocation of Euthanasia Option For The Severely Depressed
7. Fidel Castro Appeals for Investment in Health Rather Than in Arms
8. FDAs Failure Urges It to Reassess Its Policies
9. FDAs Gesture for Firm Manufacturing Drug for Cushings Syndrome
10. People suffering from Alzheimer’s: can they take decisions about their treatment
11. Decision making made easier
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/11/2008)...11 /PRNewswire-USNewswire/ -- Today, a commercial,...ed Cross relief supplies,touched down in Yangon, M...s newly arrived shipment includes an initial suppl...lp prevent the spread of malaria., "This is a ver...the,elements and vulnerable to diseases, like mala...
(Date:5/11/2008)...ought over the counter and safely used at home , ... you,re doing your spring cleaning, don,t forget y...y way for people with spring allergies, nasal cong...lief, says Dr. Melissa Pynnonen, co-director of th... in the University of Michigan,s department of oto...
(Date:5/10/2008)... 10 /PRNewswire/ -- The American Refugee Committee...ors of the tragedy in,Myanmar. In partnership with...l supplies and food, including items such as water...s to thousands of survivors., ARC will also send ...as. The team will be led by ARC Thailand Country D...
(Date:5/9/2008)...May 9 /PRNewswire-FirstCall/ -- AMDL, Inc. (Amex: ...cialty pharmaceutical company,with operations in C...rmaceutical Inc., today announced that its consoli...mber 31, 2007, which were included in its,Annual R...xchange,Commission on April 14, 2008, contained a ...
Breaking Medicine News(10 mins):Health News:Relief Supplies from American Red Cross Arrive in Myanmar 2Health News:Nasal Irrigation Can Help Fight Spring Allergies 2Health News:AMDL Reports Going Concern Qualification 2
... most common causes for referral to the emergency ...ent, is not an emergency, and intravenous treatmen...w to treat patients with acute BP elevation or exc... excessive hypertension and therefore antianxiety ...
...ave reconstructed defective windpipes using tissue...amniotic fluid for growing the sections of cartila... into lambs, while they were in the womb. This tec... birth defects. Undifferentiated stem cell from am...
...trains might have spawned an outbreak of disease a...uver Island, British Columbia, Howard Hughes Medic...l Center have reported//. The fungus, Cryptococcus...ropics and subtropics. The evidence that sex play...
...ritish High Commission organized a seminar to expl...India along with joint ventures in services and ma...ade and Investment's (UKTI) healthcare mission to ...rs in Chennai on Wednesday. The British delegation...
Other Medicine News:Health News:Anti-anxiety treatment found effective in lowering blood pressure 2Health News:Sex Played A Vital Role For Evolution Of Infectious Diseases 2
(Date:5/9/2008)...PA, Fla., May 9 /PRNewswire-USNewswire/ -- Osteoar...condition that affects almost 50,million people in...of,cartilage in bone joints. The novel investigati...g oral analgesic, provided significant relief,for ...e treated with,placebo, and with fewer gastrointes...
(Date:5/9/2008)...sts Cytopia,s development of early pipeline cancer...Newswire-FirstCall/ -- Cytopia Limited,(ASX: CYT) ...ancer drug,discovery and development collaboration...ent leverages Cytopia,s early stage drug discovery...d therapeutics that is one of the,fastest growing ...
(Date:5/8/2008)...STON, May 8 /- The Cancer Research Al...ion,s top cancer centers, is asking,303 million Am...ating $1 to,cancer research efforts this Mother,s ...he "Infinite Power of One(TM)" has two key goals:,...nto their own hands by,joining together to exercis...
(Date:5/8/2008)...eatment Provides "Blueprint" to Produce Therapeuti...l., May 8 /PRNewswire-USNewswire/ -- Using gene,th...ting proteins through,skin flaps placed on cancero...umor volume, according to a study in the May issue...icial medical journal of the American,Society of P...
Breaking Medicine Technology:Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 2Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 3Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 4Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 5Cytopia Announces Novel Anti-Cancer Drug Development Collaboration 2Cytopia Announces Novel Anti-Cancer Drug Development Collaboration 3World Renowned Cancer Centers Implore Americans to Donate $1 to Make Change and Accelerate Cancer Research 2World Renowned Cancer Centers Implore Americans to Donate $1 to Make Change and Accelerate Cancer Research 3World Renowned Cancer Centers Implore Americans to Donate $1 to Make Change and Accelerate Cancer Research 4World Renowned Cancer Centers Implore Americans to Donate $1 to Make Change and Accelerate Cancer Research 5Skin Flaps Deliver Cancer-fighting Therapy, ASPS Study Reveals 2Skin Flaps Deliver Cancer-fighting Therapy, ASPS Study Reveals 3AMDL Announces Sales of 245 8 Million for Third Quarter 2007 Results 6672 1AMDL Announces Sales of 245 8 Million for Third Quarter 2007 Results 6672 2BREATHE Lung Cancer Conference Nov 30 Offers Medical and Patient Education Advocacy and Survivors Perspective 6670 1BREATHE Lung Cancer Conference Nov 30 Offers Medical and Patient Education Advocacy and Survivors Perspective 6670 2BREATHE Lung Cancer Conference Nov 30 Offers Medical and Patient Education Advocacy and Survivors Perspective 6670 3BREATHE Lung Cancer Conference Nov 30 Offers Medical and Patient Education Advocacy and Survivors Perspective 6670 4BREATHE Lung Cancer Conference Nov 30 Offers Medical and Patient Education Advocacy and Survivors Perspective 6670 5BREATHE Lung Cancer Conference Nov 30 Offers Medical and Patient Education Advocacy and Survivors Perspective 6670 6AMICAS Solutions Closing the Loop in Radiology Communications 6668 1AMICAS Solutions Closing the Loop in Radiology Communications 6668 2AMICAS Solutions Closing the Loop in Radiology Communications 6668 3AMICAS Solutions Closing the Loop in Radiology Communications 6668 4Thoratec Announces Appointment of Steven H Collis to Board of Directors 1857 1Thoratec Announces Appointment of Steven H Collis to Board of Directors 1857 2Thoratec Announces Appointment of Steven H Collis to Board of Directors 1857 3
...INESS WIRE)--Apr 17, 2007 - A 9-month, randomized,... patients,comparing a 40 mg dose of COPAXONE(R) gi... mg dose showed a 38 percent greater,reduction in ...tic,resonance images (MRI) of the brain. In additi...a reduced mean on-trial relapse rate,of 77 percent...
...tions at American Association for Cancer Research,.../PRNewswire-FirstCall/ --,Medarex, Inc. today pres...tumor activity from two separate studies exploring...CD19 and anti-CD70,antibody-drug conjugates. CD19 ...dy-drug conjugate approach to cancer therapy. They...
Other Medicine Technology:Data Published in Neurology Showed That Higher Dose of Copaxone,Increased Efficacy in Relapsing-Remitting Multiple Sclerosis (RRMS) 2Data Published in Neurology Showed That Higher Dose of Copaxone,Increased Efficacy in Relapsing-Remitting Multiple Sclerosis (RRMS) 3Data Published in Neurology Showed That Higher Dose of Copaxone,Increased Efficacy in Relapsing-Remitting Multiple Sclerosis (RRMS) 4Data Published in Neurology Showed That Higher Dose of Copaxone,Increased Efficacy in Relapsing-Remitting Multiple Sclerosis (RRMS) 5Medarex Presents Preclinical Data Demonstrating Potent Anti-Tumor,Activity of Anti-CD19 and Anti-CD70 Antibody-Drug Conjugates in,Cancer Animal Models 2Medarex Presents Preclinical Data Demonstrating Potent Anti-Tumor,Activity of Anti-CD19 and Anti-CD70 Antibody-Drug Conjugates in,Cancer Animal Models 3Medarex Presents Preclinical Data Demonstrating Potent Anti-Tumor,Activity of Anti-CD19 and Anti-CD70 Antibody-Drug Conjugates in,Cancer Animal Models 4
...boratories is a national reference laboratory and ...ch and development. ARUP offers an extensive test ... clinical and anatomic pathology. Owned by the Uni...e more than half of the nation's university teachi...
...boratories is a national reference laboratory and ...ch and development. ARUP offers an extensive test ... clinical and anatomic pathology. Owned by the Uni...e more than half of the nation's university teachi...
...boratories is a national reference laboratory and ...ch and development. ARUP offers an extensive test ... clinical and anatomic pathology. Owned by the Uni...e more than half of the nation's university teachi...
...boratories is a national reference laboratory and ...ch and development. ARUP offers an extensive test ... clinical and anatomic pathology. Owned by the Uni...e more than half of the nation's university teachi...
Medicine Products: